| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5104784 | Value in Health | 2017 | 10 Pages |
Abstract
Implementing germline BRCA testing in all patients with ovarian cancer would be cost-effective in the United Kingdom. The consequent reduction in future cases of breast and ovarian cancer in relatives of mutation-positive individuals would ease the burden of cancer treatments in subsequent years and result in significantly better outcomes and reduced mortality rates for these individuals.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Anthony MMathStat, Anthony MSc, Matthew MSc, Ann BSc (Hons), Wim MSc, Angela MBChB, FRACP, MD, Nazneen BMBCh, FRCP, PhD,